Get the Stockscreener App
2.78
0.00%
0.00
After Hours:
2.75
-0.03
-1.08%
Anixa Biosciences Inc stock is traded at $2.78, with a volume of 355.79K.
It is up +0.00% in the last 24 hours and down -24.04% over the past month.
Anixa Biosciences Inc is a biotechnology company developing therapies and vaccines focused on critical unmet needs in oncology. Its operations are organized into reportable segments comprising Cancer Vaccines, CAR-T Therapies, and Other. The Cancer Vaccines segment involves vaccines to treat and prevent breast and ovarian cancer, as well as additional cancer vaccines targeting intractable cancers, including high-incidence malignancies in lung, colon, and prostate. The CAR-T Therapies segment involves the development of liraltagene autoleucel (lira-cel), an ovarian cancer immunotherapy using chimeric endocrine receptor-T cell technology, developed at its subsidiary, Certainty Therapeutics, Inc. The Other segment consists of legacy operations, including limited patent licensing activities.
See More
Previous Close:
$2.78
Open:
$2.85
24h Volume:
355.79K
Relative Volume:
1.15
Market Cap:
$96.64M
Revenue:
$210.00K
Net Income/Loss:
$-10.12M
P/E Ratio:
-9.1689
EPS:
-0.3032
Net Cash Flow:
$-7.12M
1W Performance:
+0.36%
1M Performance:
-24.04%
6M Performance:
+2.96%
1Y Performance:
-17.63%
1-Day Range:
$2.69
$2.87
1-Week Range:
$2.62
$2.87
52-Week Range:
$2.32
$5.4566
Anixa Biosciences Inc Stock (ANIX) Company Profile
Name
Anixa Biosciences Inc
Sector
Industry
Phone
408-708-9808
Address
3150 ALMADEN EXPRESSWAY, SUITE 250, SAN JOSE
Compare ANIX vs VRTX, REGN, MRNA, ARGX, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ANIX
Anixa Biosciences Inc
|
2.78 | 96.64M | 210.00K | -10.12M | -7.12M | -0.3032 |
VRTX
Vertex Pharmaceuticals Inc
|
526.19 | 133.37B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
788.04 | 81.13B | 14.92B | 4.42B | 3.79B | 41.04 |
MRNA
Moderna Inc
|
198.88 | 79.40B | 2.23B | -3.19B | -1.60B | -8.1462 |
ARGX
Argen X Se Adr
|
959.49 | 60.03B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
204.97 | 43.93B | 742.00K | -1.37B | -1.07B | -7.0731 |
Anixa Biosciences Inc Stock (ANIX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-21-25 | Initiated | Maxim Group | Buy |
| Dec-23-22 | Initiated | Chardan Capital Markets | Buy |
| Apr-12-21 | Initiated | H.C. Wainwright | Buy |
Anixa Biosciences Inc Stock (ANIX) Latest News
Form 4 Anixa Biosciences Inc For: 25 September By Investing.com - Investing.com Nigeria
Anixa Biosciences (NASDAQ:ANIX) Director Lewis Titterton Jr Purchases 49,036 Shares of Company Stock - MarketBeat
Director Titterton Lewis H jr Buys 49,036 Shares of Anixa Biosci - GuruFocus
Anixa Biosciences director Lewis Titterton Jr. buys $131,906 in stock - Investing.com
Form 4 Anixa Biosciences Inc For: 25 September - Investing.com India
At $2.69 a share, an Anixa Biosciences (ANIX) director buys stock, bringing his direct holdings to 1,046,003 shares. - stocktitan.net
H.C. Wainwright lowers Anixa Biosciences stock price target to $6 By Investing.com - Investing.com Australia
H.C. Wainwright lowers Anixa Biosciences stock price target to $6 - Investing.com
ANIX Maintained by HC Wainwright & Co. -- Price Target Lowered t - GuruFocus
H.C. Wainwright Maintains Anixa Biosciences(ANIX.US) With Buy Rating, Cuts Target Price to $6 - Moomoo
HC Wainwright Has Lowered Expectations for Anixa Biosciences (NASDAQ:ANIX) Stock Price - MarketBeat
HC Wainwright & Co. maintains Buy rating on Anixa Biosciences, $6 price target - TradingView
Anixa Biosciences secures Australian patent for breast cancer vaccine - scanx.trade
Anixa advances ovarian cancer CAR-T trial to highest dose level - scanx.trade
Anixa Biosciences (ANIX) Secures Australian Patent for Breast Ca - GuruFocus
Anixa receives Australian patent for breast cancer vaccine By Investing.com - Investing.com Canada
Anixa receives Australian patent for breast cancer vaccine - Investing.com
Anixa secures exclusive patent for breast cance... - Pluang
Anixa Biosciences Granted First Australian Patent for its Breast Cancer Vaccine, Broadening Global Protection Through 2040 - PR Newswire
Anixa Biosciences Inc (NASDAQ:ANIX) Receives Consensus Rating of "Hold" from Brokerages - MarketBeat
Anixa Biosciences adds UPenn oncologist to advisory board By Investing.com - Investing.com Nigeria
Anixa Biosciences Adds Penn Cancer Expert Carmen Guerra to Advisory Board - citybiz
Anixa Biosciences adds UPenn oncologist to advisory board - Investing.com
Anixa Biosciences Appoints UPenn's Dr. Carmen Guerra to Cancer Business Advisory Board - streetinsider.com
Anixa Biosciences (ANIX) CEO Amit Kumar Buys 3,000 Shares, Insider Ownership Rises to 665,000 Shares - GuruFocus
Anixa Biosciences CEO Amit Kumar buys $8,250 in ANIX common stock - Investing.com Nigeria
Anixa Biosciences director Lewis Titterton Jr. buys $27,300 in stock - Investing.com
Anixa Biosciences director Lewis Titterton Jr. buys $27,300 in stock By Investing.com - Investing.com Nigeria
Anixa Biosciences (NASDAQ: ANIX) CEO lifts stake to 665,000 shares - Stock Titan
Anixa Biosciences (ANIX) director buys 10,000 shares - stocktitan.net
Anixa Biosciences (ANIX) CEO Amit Kumar Buys 5,000 Shares, Insider Ownership Climbs to 662,000 - GuruFocus
Anixa Biosciences CEO Amit Kumar acquires $13,799 in stock By Investing.com - Investing.com Canada
Anixa Biosciences CEO Amit Kumar acquires $13,799 in stock - investing.com
Amit Kumar Acquires 5,000 Shares of Anixa Biosciences (NASDAQ:ANIX) Stock - marketbeat.com
Anixa Biosciences and Nexalin Technology Interviews to Air Nationally on the RedChip Small Stocks, Big Money(TM) Show on CNBC and Bloomberg TV - ACCESS Newswire
ANIX: Innovative cancer therapies advance in clinic, supported by strong partnerships and financial discipline - TradingView
Anixa Biosciences at H.C. Wainwright: two cancer bets advance By Investing.com - Investing.com Canada
Anixa Biosciences at H.C. Wainwright: two cancer bets advance - Investing.com India
Anixa Biosciences (ANIX) CEO lifts stake to 662,000 shares - Stock Titan
Anixa Biosciences Q3 Results: EPS beats estimate, sales flat - scanx.trade
Anixa Biosciences (NASDAQ:ANIX) Issues Quarterly Earnings Results - marketbeat.com
Anixa Biosciences Inc reports results for the quarter ended July 31Earnings Summary - TradingView
Anixa Biosciences highlights progress in breast cancer vaccine on Bloomberg TV this Saturday. - Pluang
A breast cancer survivor will discuss Anixa's vaccine on TV - Stock Titan
Anixa Biosciences Inc expected to post a loss of 9 cents a shareEarnings Preview - TradingView
Anixa Biosciences Inc. (ANIX) Shareholding Pattern – Promoters, FIIs & DIIs - Value Research
Anixa Biosciences Inc. (ANIX) Financials – Balance Sheet, Profit & Loss, Cash Flow - Value Research
Anixa Biosciences to Present at the Nasdaq & LD Micro Inaugural SF Summit on September 9, 2026 - PR Newswire
Anixa Biosciences (ANIX) Projected to Post Earnings on Wednesday - MarketBeat
Anixa Biosciences (ANIX) Sheds 1.5% to $3.60 as Biotech Momentum CoolsVolume Breakout Ideas - siam.in
Anixa Biosciences to Present at the 2026 Cantor Fitzgerald Global Healthcare Conference Highlighting its Breast Cancer Vaccine and Ovarian Cancer CAR-T Therapy - AOL.ca
Anixa Biosciences Inc Stock (ANIX) Financials Data
Revenue
Net Income
Cash Flow
EPS
3.06%
2.55%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):